Disease overview

Alterations

144

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

224

Natural agents

Natural products

Merged ranked

277

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

PV/ET/MF: no spontaneous remission; progressive disorders with risk of transformation to MF (PV/ET) and blast phase (all); median survival PV >20 years, MF 5-7 years

Best-intervention remission

JAK2 inhibitor (ruxolitinib) for MF/PV: 35-42% spleen volume reduction, significant symptom improvement; ropeginterferon alfa-2b: superior complete haematological response vs hydroxyurea (PROUD-PV); allogeneic HSCT (MF): curative in 30-60% of transplant-eligible patients

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate — ruxolitinib is established but HSCT underused in eligible MF patients; ropeginterferon is superior in PV but access varies

Primary barrier

access/practice

Barrier detail: Hydroxyurea remains the most common cytoreductive agent for PV/ET despite ropeginterferon demonstrating superior molecular response; HSCT for MF is underutilised in patients who could benefit; JAK2 mutation molecular monitoring not performed systematically

Last SoC change: 2022 — ropeginterferon alfa-2b (Besremi) FDA approved for PV; 2019 fedratinib (JAK2/FLT3) for MF; pacritinib 2022 for thrombocytopenic MF; ruxolitinib 2011 for MF, 2014 for PV; hydroxyurea standard since 1960s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0009891

Alterations

Showing 80 of 144 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abdominal pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of vision	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Acute leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Angina pectoris	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Arterial thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Arthralgia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Bruising susceptibility	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Budd-Chiari syndrome	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral hemorrhage	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cerebral ischemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Early satiety	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Epistaxis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Erythromelalgia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Fatigue	Functional	Functional test	—	—	Moderate	HPO, Monarch	HPO
Gastrointestinal hemorrhage	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Gingival bleeding	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Headache	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hepatomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypertension	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased circulating hemoglobin concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Increased hematocrit	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased megakaryocyte count	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased red blood cell mass	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased total leukocyte count	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Intermittent claudication	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myelodysplasia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Myelofibrosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Paresthesia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polycythemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Portal hypertension	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Portal vein thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pruritus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pulmonary embolism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Respiratory insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Splenomegaly	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Stroke	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thrombocytopenia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thrombocytosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Thromboembolism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Tinnitus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Venous thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vertigo	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABHD6 abhydrolase domain containing 6, acylglycerol lipase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACVR1 activin A receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AFG1L AFG1 like ATPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APC APC regulator of Wnt signaling pathway	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASXL1 ASXL transcriptional regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATG10 autophagy related 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCOR BCL6 corepressor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCR BCR activator of RhoGEF and GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CALR calreticulin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CBL Cbl proto-oncogene	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CELF2 CUGBP Elav-like family member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLMB calcimembrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL19A1 collagen type XIX alpha 1 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNMT3A DNA methyltransferase 3 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DPP8 dipeptidyl peptidase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DPT dermatopontin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EP300 EP300 lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPAS1 endothelial PAS domain protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAT4 FAT atypical cadherin 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT3 fms related receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA2 GATA binding protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA3 GATA binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GFI1B growth factor independent 1B transcriptional repressor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNAS GNAS complex locus	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GYPA glycophorin A (MNS blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC1 histone deacetylase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC10 histone deacetylase 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDAC11 histone deacetylase 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVAPRITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CEMIPLIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CERITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DECITABINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DENOSUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ANAGRELIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GIVINOSTAT	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYDROXYUREA	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2A	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NOVAFERON	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PIPOBROMAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RUSFERTIDE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SAPABLURSEN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BOMEDEMSTAT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CLOPIDOGREL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DASATINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DASATINIB ANHYDROUS	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DOXORUBICIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ETOPOSIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
GANDOTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IDASANUTLIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IMATINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IMATINIB MESYLATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IMETELSTAT	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LESTAURTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LUMINESPIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MIRABEGRON	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MOMELOTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NAVTEMADLIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
VINCRISTINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ZINPENTRAXIN ALFA	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
POMALIDOMIDE	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via APC	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing via ABHD6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABHD6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AVAPRITINIB Repurposing via CBL	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABHD6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via APC	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BLINATUMOMAB Repurposing via BCR	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing via BCR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BRENTUXIMAB VEDOTIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSULFAN Repurposing via BCR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CABOZANTINIB S-MALATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABHD6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing via APC	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CEMIPLIMAB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CERITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABHD6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Polycythaemia Vera / Myeloproliferative Neoplasms

Disease overview

Remission & chronicity

Alterations

Therapeutics

Part of the Open Source Medicine Foundation Network